The G-EYE Colonoscope was found to increase detection rate of colon adenomas compared to ECV technology. Credit: SMART Medical Systems / PRNewswire.

SMART Medical Systems has announced that its G-Eye balloon technology showed an increase in the detection rate of colon adenomas in a clinical trial compared to Endocuff Vision (ECV) technology.

The randomised, multicentre clinical study (NCT 04708951) compared the adenoma detection rate (ADR) of its technology, which is cleared by the US Food and Drug Administration (FDA) in patients undergoing colonoscopy screening.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company stated that the ADR, especially for advanced and large adenomas, was higher for the G-EYE balloon compared to ECV attachment in the trial.

Colonoscopy is colorectal cancer (CRC) prevention’s gold standard, but folds within the colon may harbour adenomas (pre-cancerous polyps) that cannot be seen during the exam.

It is noted that both the technologies are designed to assist colonoscopy by mechanical manipulation increasing colon surface area exposure.

In the trial, 935 patients with similar characteristics were randomised for G-Eye or ECV-assisted colonoscopy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was found that the ADR of patients using G-EYE technology increased by 18% overall and a 69% increase was observed in advanced adenomas ADR.

Furthermore, the detection of an additional 83% large adenomas and 87% advanced adenomas was supported by G-EYE compared to ECV.

SMART Medical CEO Gadi Terliuc said: “The effect of the G-EYE balloon is notable, and I expect it to become a standard tool, over time, for every colonoscopy.

“These new data add to the growing body of clinical evidence demonstrating that G-EYE provides endoscopists with increased diagnostic yield, and we are gratified that the American College of Gastroenterology (ACG) has recognised the importance of these findings by selecting this abstract for the Outstanding Research Award in the colon cancer prevention category.”